disclaimer

Bozo.Finance. A Groundbreaking NFTxTOKEN Solution Revolutionizing Decentralized Finance.

Source Node:
Time Stamp: February 1, 2024 10:47 AM - Modified On: February 1, 2024 - Published By:
Source Cluster:
Republished By Plato

  Bozo.Finance / Bozo Hybrid In an innovative leap forward for the DeFi space, Bozo Hybrid announces the launch of its revolutionary platform - a first-of-its-kind NFTxTOKEN hybrid that is reshaping the landscape of liquidity and asset interchangeability. The Game-Changing Innovation of Bozo HYBRID Bozo HYBRID is not just another project in the blockchain space. It represents a paradigm shift, a true DeFi 2.0 model, by integrating non-fungible tokens (NFTs) with fungible tokens ($bozo tokens) to create a two-way liquidity portal. This hybrid approach is a breakthrough in the market,

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:54 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial